The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Heterogeneity in Nectin-4 expression across molecular subtypes of urothelial cancer mediates sensitivity to enfortumab vedotin.
Carissa Chu
No Relationships to Disclose
Martin Sjöström
Research Funding - PFS Genomics (Inst); PFS Genomics (Inst)
Emily A Egusa
No Relationships to Disclose
Ewan Gibb
Employment - Decipher Biosciences
Michelle L Badura
No Relationships to Disclose
Vadim S Koshkin
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Dendreon; Gerson Lehrman Group; Guidepoint Global; Janssen; Pfizer/EMD Serono; Seattle Genetics/Astellas
Speakers' Bureau - Seattle Genetics/Astellas
Research Funding - Clovis Oncology; Endocyte; Nektar
Travel, Accommodations, Expenses - AstraZeneca; Janssen
Bradley A. Stohr
No Relationships to Disclose
Maxwell Meng
No Relationships to Disclose
Raj Pruthi
No Relationships to Disclose
Terence W. Friedlander
Leadership - Med BioGene
Honoraria - AstraZeneca/MedImmune; EMD Serono; Seattle Genetics/Astellas; Seattle Genetics/Astellas
Consulting or Advisory Role - Abbvie; Abbvie; AstraZeneca; Dava Oncology; Dendreon; Foundation Medicine; Janssen; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Incyte (Inst); Janssen; Neon Therapeutics (Inst); Seattle Genetics (Inst)
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Genentech/Roche; Jounce Therapeutics
Yair Lotan
Stock and Other Ownership Interests - CAPS Medical; Vessi Medical
Consulting or Advisory Role - Abbvie; AstraZeneca; Bristol-Myers Squibb; Cleveland Diagnostics; Fergene; Fergene; Merck; Nucleix; pacific edge; Photocure; Urogen pharma; Vessi Medical
Research Funding - Abbott Molecular (Inst); Augmenix; BioCancell (Inst); Cepheid; Cepheid (Inst); GenomeDx (Inst); MDxHealth (Inst); pacific edge; pacific edge (Inst); Photocure (Inst); storz (Inst)
Peter C. Black
Consulting or Advisory Role - Abbvie; Amgen; Asieris Pharmaceuticals; Asieris Pharmaceuticals; Astellas Pharma; AstraZeneca; Bayer; Biosyent; Bristol-Myers Squibb; EMD Serono; Ferring; H3 Biomedicine; Janssen Oncology; MDxHealth; Merck; Roche Canada; Sanofi; Urogen pharma
Speakers' Bureau - Pfizer; TerSera
Research Funding - GenomeDx; GlaxoSmithKline; iProgen; Sitka
Patents, Royalties, Other Intellectual Property - 1. PCT/CA2014/000787. Canada. 2014-11-03 Cancer Biomarkers and Classifiers and uses thereof. 2. #61899648 United States. 2013-03-13 Bladder cancer signature.
Travel, Accommodations, Expenses - Sanofi
Other Relationship - Sanofi
Sima P. Porten
Honoraria - photocure
Consulting or Advisory Role - Bristol-Myers Squibb; KDx Diagnostics; Photocure
Research Funding - Photocure (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
Felix Y Feng
Leadership - PFS Genomics
Stock and Other Ownership Interests - PFS Genomics
Honoraria - Genentech
Consulting or Advisory Role - Astellas Pharma; Blue Earth Diagnostics; Celgene; Genentech; Janssen Biotech; Myovant Sciences; Roivant; SerImmune
Research Funding - Zenith Epigenetics
Patents, Royalties, Other Intellectual Property - I helped develop a molecular signature to predict radiation resistance in breast cancer, and this signature was patented by the University of Michigan, my employer. It is in the process of being licensed to PFS Genomics, a company that I helped found. (Inst)
Jonathan Chou
Stock and Other Ownership Interests - Array BioPharma (I); Atara Biotherapeutics (I); Bluebird Bio (I); Celgene (I); Exelixis (I)
Research Funding - Amgen Astellas BioPharma (Inst)